RetroVirox Announces Appointment of Dr. Ronald C. Griffith as Vice President of Research and Development

SAN DIEGO, CA, Oct 08 (MARKET WIRE) --
RetroVirox, Inc., a biotechnology company focused on developing novel
antivirals, announced today the appointment of Ronald C. Griffith, Ph.D.
as Vice President of Research and Development, effective September 15th,
2009. Dr. Griffith will report to Juan Lama, Ph.D., founder and CEO of
RetroVirox and will also become a member of the company's Board of
Directors.

Dr. Griffith brings to RetroVirox more than 30 years of experience in the
biotechnology and pharmaceutical industries. Prior to joining RetroVirox,
Dr. Griffith was Chief Scientific Officer of Genelabs Technologies, a
virology company in Redwood City, California. Earlier this year, Genelabs
was acquired by GlaxoSmithKline. At Genelabs, Dr. Griffith built a
scientific team of over fifty scientists (30 Ph.D.'s) and oversaw all
internal research and development programs, including the company's HCV
projects. Dr. Griffith was instrumental in closing HCV partnership deals
with Gilead Science and Novartis, valued at $300 million. Previously, he
spent 23 years at AstraZeneca Pharmaceuticals and held Vice President
positions in Tanabe Research Laboratories, X-Ceptor Therapeutics, and Isis
Pharmaceuticals. Dr. Griffith received his Ph.D. in Organic Chemistry from
Syracuse University and performed his post-doctoral studies at the
California Institute of Technology.

"We are very pleased to welcome Dr. Griffith to the RetroVirox senior
management team," said Juan Lama, Ph.D., founder and Chief Executive
Officer of RetroVirox, Inc. "Dr. Griffith brings tremendous value to the
company, with a unique combination of innovation in antiviral discovery,
partnering experience, and expertise in driving new drugs into clinical
development." At RetroVirox, Dr. Griffith will direct the small-molecule
drug development programs for HIV and HCV. "I am delighted to join
RetroVirox and look forward to working with management and this innovative
team of scientists."

Along with Dr. Griffith, Richard Martin, Ph.D. joins the company as
Director of Chemistry, and Richard W. Michitsch, Ph.D. has been appointed
Director of Screening Operations. Combined, this team brings over 60 years
of experience in drug discovery and development, 20 IND filings, and 2
compounds to FDA approval.

About RetroVirox

RetroVirox, Inc. is a privately held company headquartered in San Diego,
California, developing novel drugs to treat some of the most challenging
human pathogens, including HIV and HCV. The company is currently raising
Series A financing.

For more information visit http://www.retrovirox.com/ or email us at
info@retrovirox.com

Contact:
Juan Lama, Ph.D
858-436-2191
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-